Soluble TL1A is sufficient for activation of death receptor 3.
Death receptor 3 (DR3) is a typical member of the tumor necrosis factor receptor family, and was initially identified as a T-cell co-stimulatory molecule. However, further studies revealed a more complex and partly dichotomous role for DR3 and its ligand TL1A under (patho)physiological conditions. TL1A and DR3 are not only a driving force in the development of autoimmune and inflammatory diseases, but also play an important role in counteracting these processes through an increase in the number of regulatory T cells. Ligands of the tumor necrosis factor family typically occur in two forms, membrane-bound and soluble, that can differ strikingly with respect to their efficacy in activating their corresponding receptor(s). Ligand-based approaches to activate the TL1A-DR3 pathway therefore require understanding of the molecular prerequisites of TL1A-based DR3 activation. To date, this has not been addressed. Here, we show that recombinant soluble trimeric TL1A is fully sufficient to strongly activate DR3-associated pro- and anti-apoptotic signaling pathways. In contrast to the TRAIL death receptors, which are much better activated by soluble TRAIL upon secondary ligand oligomerization, but similarly to the death receptor tumor necrosis factor receptor 1, DR3 is efficiently activated by soluble TL1A trimers. Additionally, we have measured the affinity of TL1A-DR3 interaction in a cell-based system, and demonstrated TL1A-induced DR3 internalization. Identification of DR3 as a tumor necrosis factor receptor that responds to soluble ligand trimers without further oligomerization provides a basis for therapeutic exploitation of the TL1A-DR3 pathway.
Institute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, Germany.
Sebastian
S
Bittner
Institute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, Germany.
Gertrud
G
Knoll
Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Germany.
Simone
S
Füllsack
Institute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, Germany.
Maria
M
Kurz
Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Germany.
Harald
H
Wajant
Institute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, Germany.
Martin
M
Ehrenschwender
D016923:Cell Death; D057809:HEK293 Cells; D006367:HeLa Cells; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D055503:Protein Multimerization; D053219:Receptors, Tumor Necrosis Factor, Member 25 / Q000235:genetics / Q000378:metabolism*; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D012995:Solubility; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15 / Q000235:genetics / Q000378:metabolism*
D016209:Interleukin-8; D016328:NF-kappa B; D053219:Receptors, Tumor Necrosis Factor, Member 25; D047889:Receptors, Tumor Necrosis Factor, Type II; D011994:Recombinant Proteins; C506033:TNFRSF25 protein, human; C117026:TNFSF15 protein, human; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15
DR3; TL1A; TNFRSF25; TNFSF15; death receptor